Abbott Laboratories (NYSE: ABT) made headlines this year after closing a $21 billion cash deal to acquire Exact Sciences, a company focused on cancer diagnostics. The acquisition targets one of Abbott’s slower-growing business units and signals a strategic push to strengthen its diagnostic capabilities in an increasingly competitive healthcare market. Abbott also leads the continuous […]
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.